Sarepta Therapeutics Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi

Sarepta recently secured conditional approval for its gene-editing therapy. But the therapy's high price tag might slow down its uptake among patients.

Doug Ingram, Sarepta Therapeutics CEO, joins 'Squawk on the Street' to discuss the FDA's concerns with Sarepta's latest approval, how confident Ingram is the company's latest drug approval won't get r

On May 15, Sarepta Therapeutics Inc. NASDAQ: SRPT learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA) advisors. Natu

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Sarepta Therapeutics shares slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enou

The $3.2 million one-time treatment is the first gene therapy approved to treat DMD, a progressive and fatal condition that manifests in early childhood.

Sarepta Therapeutics Inc. SRPT, -2.33%, which yesterday scored a win with U.S. Food and Drug Administration approval of the first gene therapy for children with Duchenne muscular dystrophy, was downgr

Sarepta Therapeutics Inc (NASDAQ:SRPT) said the US Food and Drug Administration (FDA) has accelerated approval for ELEVIDYS, its first-of-a-kind gene therapy for Duchenne muscular dystrophy (DMD). DMD

WASHINGTON — The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's abil

The decision marks the first approval of a gene therapy to treat DMD, a fatal and progressive disease that manifests in young children.

Sarepta won approval Thursday for its highly anticipated Duchenne muscular dystrophy gene therapy. SRPT stock yo-yoed in response.

Sarepta Therapeutics Inc. SRPT, +0.60% said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the rare genetic disorder Duchenne muscular dystrophy, or DMD. Sa

The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics' first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD), an inherited progressive muscle wasting

Sarepta Therapeutics should earn ~$1bn from its Duchenne Muscular Dystrophy franchise in 2023 - although the company has made eye-watering losses in recent years. Sarepta ought to hear any day whether